Integra Lifesciences Holdings Stock Net Income
| IART Stock | USD 11.90 0.29 2.38% |
As of the 24th of January, Integra LifeSciences retains the Standard Deviation of 4.15, market risk adjusted performance of (0.17), and Risk Adjusted Performance of (0.06). Integra LifeSciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Integra LifeSciences' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Integra LifeSciences' valuation are summarized below:Integra LifeSciences Holdings does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integra LifeSciences. If investors know Integra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integra LifeSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Integra LifeSciences is measured differently than its book value, which is the value of Integra that is recorded on the company's balance sheet. Investors also form their own opinion of Integra LifeSciences' value that differs from its market value or its book value, called intrinsic value, which is Integra LifeSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integra LifeSciences' market value can be influenced by many factors that don't directly affect Integra LifeSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integra LifeSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Integra LifeSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integra LifeSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Integra LifeSciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Integra LifeSciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Integra LifeSciences.
| 10/26/2025 |
| 01/24/2026 |
If you would invest 0.00 in Integra LifeSciences on October 26, 2025 and sell it all today you would earn a total of 0.00 from holding Integra LifeSciences Holdings or generate 0.0% return on investment in Integra LifeSciences over 90 days. Integra LifeSciences is related to or competes with Tandem Diabetes, Pacific Biosciences, Maravai Lifesciences, Septerna Common, Fortrea Holdings, Myriad Genetics, and Bicara Therapeutics. Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments ... More
Integra LifeSciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Integra LifeSciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Integra LifeSciences Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 23.46 | |||
| Value At Risk | (4.33) | |||
| Potential Upside | 5.4 |
Integra LifeSciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Integra LifeSciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Integra LifeSciences' standard deviation. In reality, there are many statistical measures that can use Integra LifeSciences historical prices to predict the future Integra LifeSciences' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.78) | |||
| Treynor Ratio | (0.18) |
Integra LifeSciences January 24, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.17) | |||
| Mean Deviation | 2.47 | |||
| Coefficient Of Variation | (1,078) | |||
| Standard Deviation | 4.15 | |||
| Variance | 17.21 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.78) | |||
| Treynor Ratio | (0.18) | |||
| Maximum Drawdown | 23.46 | |||
| Value At Risk | (4.33) | |||
| Potential Upside | 5.4 | |||
| Skewness | (2.55) | |||
| Kurtosis | 15.62 |
Integra LifeSciences Backtested Returns
Integra LifeSciences holds Efficiency (Sharpe) Ratio of -0.0928, which attests that the entity had a -0.0928 % return per unit of risk over the last 3 months. Integra LifeSciences exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Integra LifeSciences' Standard Deviation of 4.15, risk adjusted performance of (0.06), and Market Risk Adjusted Performance of (0.17) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 2.17, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Integra LifeSciences will likely underperform. At this point, Integra LifeSciences has a negative expected return of -0.38%. Please make sure to check out Integra LifeSciences' maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if Integra LifeSciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.21 |
Weak predictability
Integra LifeSciences Holdings has weak predictability. Overlapping area represents the amount of predictability between Integra LifeSciences time series from 26th of October 2025 to 10th of December 2025 and 10th of December 2025 to 24th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Integra LifeSciences price movement. The serial correlation of 0.21 indicates that over 21.0% of current Integra LifeSciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.21 | |
| Spearman Rank Test | -0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.32 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Integra LifeSciences Holdings reported net income of (6.94 Million). This is 102.03% lower than that of the Health Care Equipment & Supplies sector and 102.92% lower than that of the Health Care industry. The net income for all United States stocks is 101.22% higher than that of the company.
Integra Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integra LifeSciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Integra LifeSciences could also be used in its relative valuation, which is a method of valuing Integra LifeSciences by comparing valuation metrics of similar companies.Integra LifeSciences is currently under evaluation in net income category among its peers.
Integra Fundamentals
| Return On Equity | -0.39 | ||||
| Return On Asset | 0.0261 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 2.69 B | ||||
| Shares Outstanding | 77.89 M | ||||
| Shares Owned By Insiders | 13.95 % | ||||
| Shares Owned By Institutions | 96.43 % | ||||
| Number Of Shares Shorted | 7.37 M | ||||
| Price To Earning | 26.94 X | ||||
| Price To Book | 0.92 X | ||||
| Price To Sales | 0.58 X | ||||
| Revenue | 1.61 B | ||||
| Gross Profit | 944.73 M | ||||
| EBITDA | 193.29 M | ||||
| Net Income | (6.94 M) | ||||
| Cash And Equivalents | 451.52 M | ||||
| Cash Per Share | 5.41 X | ||||
| Total Debt | 1.98 B | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 3.85 X | ||||
| Book Value Per Share | 13.33 X | ||||
| Cash Flow From Operations | 129.38 M | ||||
| Short Ratio | 9.64 X | ||||
| Earnings Per Share | (6.47) X | ||||
| Price To Earnings To Growth | 0.71 X | ||||
| Target Price | 15.5 | ||||
| Number Of Employees | 4.4 K | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 949.73 M | ||||
| Total Asset | 4.04 B | ||||
| Retained Earnings | 939.91 M | ||||
| Working Capital | 159.56 M | ||||
| Current Asset | 438.5 M | ||||
| Current Liabilities | 139.13 M | ||||
| Net Asset | 4.04 B |
About Integra LifeSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Integra LifeSciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integra LifeSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integra LifeSciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.